



New Positive Data on TROGARZO™ (ibalizumab-uiyk) injection and EGRIFTA® (tesamorelin for injection) Presented at 25th Conference on Retroviruses and Opportunistic Infections

March 8, 2018

Theratechnologies Inc. (Theratechnologies) (TSX:TH) today presented new results from additional analyses based on studies conducted with Trogarzo™ and EGRIFTA®. The study conclusions were unveiled during the 25th Conference on Retroviruses and Opportunistic Infections (CROI) which is now being held in Boston, Massachusetts.